Tuesday 27 February 2018

How Missed Red Flags Derailed Drug Deal

Akorn's checkered history should have given Fresenius pause before it agreed to buy the generic-drug company.

from WSJ.com: Markets http://ift.tt/2FCVq52
via https://ifttt.com/ IFTTT
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)